---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-24-000031"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:24:30.006925+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Denali Therapeutics outlines 2024 pipeline milestones, plans to spin out preclinical small molecule portfolio

## Summary
- Cash of ~$1.12B as of Sep 30, 2023; expects 2024 OpEx ≤2023, extending runway into 2027.
- Plans to complete enrollment in late-stage MPS II (COMPASS) and ALS (HEALEY) trials in 2024.
- DNL593 (PTV:PGRN) Phase 1/2 paused for protocol modifications after infusion-related reactions in 2 participants.
- Announces spin-out of preclinical small molecule portfolio into a separately funded NewCo.
- IND-enabling studies for OTV:MAPT (Alzheimer's) and OTV:SNCA (Parkinson's) expected in 2024.

## SEC filing metadata
- accession: 0001714899-24-000031
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000031/0001714899-24-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489924000031/dnli-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-24-000031
- JSON: https://secwatch.observer/filing/0001714899-24-000031.json
- Plain text: https://secwatch.observer/filing/0001714899-24-000031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.